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 SUPPLEMENTAL DATA 
 
Supplementary methods: Statistical analysis 
The longitudinal outcome variables studied here differ importantly with regards to the 
following characteristics: their distribution (including excess of zero values), the 
frequency and duration of data collection (see Supplementary Table 2), data 
availability/density at every follow-up, the kinetic of their median (see Supplementary 
Figure 1), mean and variance. Based on every variable’s specific summary statistics, 
availability and distribution over time, the dataset was censored at different time 
points for different outcome variables (for example, year 5 for DAS28 but year 10 for 
HAQ in NOAR) and the appropriate model was used for every outcome variable. 
GLLAMM was performed with discrete random effects and three latent classes. This 
implies a finite mixture of three-component normal distributions for the Larsen score 
or the number of erosions to capture their extra zero scores and their distribution 
skewness. Effect sizes are given as an increase in Larsen unit or in the number of 
erosions. Adjustment for age, disease duration and the square of them was 
performed to allow for a quadratic relationship between radiographic outcome and 
time/age. GLLAMM is usually inappropriate if too few time points are available or 
shows convergence problems if more than two polynomial terms for disease duration 
and age need to be fitted (non-convergence problem for cubic relationships or 
above). Therefore, when fitting polynoms of higher order was needed to improve 
model accuracy, we used quantile (median) regression or ZINB.[23] The entire 
cohort (see Supplementary Tables 1 and 2) was used to determine the order of the 
polynoms of age and disease duration; polynomial terms of increasing order were 
added sequentially, as long as they were significantly associated with disease 
outcome at the 0.05 level (Supplementary Figure 1). The standard error of parameter 
estimates in quantile regression was obtained with a bootstrap method with 500 
iterations to stringently correct for intra-individual correlation.  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. Modelling the effect of disease duration and age on 
measures of disease outcome 
Disease duration is the strongest predictor of disease severity and could therefore 
potentially mask the weak association of a genetic marker. The entire NOAR cohort 
(irrespective of the availability of genetic information) comprising 4293 patients 
followed up over time was used to determine the relationship between time or age 
and outcome variables. The predicted kinetic of the median HAQ score is shown 
here (upper panels), when a polynom of disease duration or age is used to model 
HAQ scores. Lower panels show the predicted Swollen Joint Count modelled with a 
polynom of disease duration or age. The same approach was used in ERAS. 
  
  
  
  
Supplementary Table 1. Characteristics of patients with inflammatory 
polyarthritis (IP) 
Erosive disease was defined as the presence of at least one erosive joint (Larsen 
score ≥ 2) according to Larsen: cortical break ≥ 2 mm. IP: inflammatory polyarthritis. 
RA: rheumatoid arthritis, i.e. patients who satisfied at any point the 1987 American 
College of Rheumatology (ACR) criteria applied cumulatively over the 5 first years of 
the follow-up. SE: shared epitope. DMARDs: disease modifying anti-rheumatic 
drugs. "-" not relevant. IQR: interquartile range. Anti-CCP: anticyclic citrullinated 
peptide. 
  
 
Entire cohort 
With genotype for 
the SE 
With genotype for 
FOXO3A 
Number of patients with IP, baseline 
(year 5,10,15,20) 
4293 (2934, 892, 
530, 175) 
2673 (2067, 785, 
481, 157) 
2350 (1822, 710, 
454, 158) 
Total number of follow-ups 24093 17132 15137 
Duration of follow-up in yrs, median 
(range) 
3 (0-20) - - 
Number of follow-ups per patient, 
median (range) 
4 (1-13) - - 
Number of patients with RA (%) 2537 (59) 1846 (69) 1613 (69) 
Number of female (%) 2779 (65) 1761 (66) 1547 (66) 
Age at symptom onset in yrs, median 
(IQR) 
55 (42-67) 55 (43-67) 55 (43-67) 
Ever positive for anti-CCP (%) 32 34 33 
On a DMARD at year 0, 1, 5, 10, 20 (%) 31, 46, 48, 42, 37 - - 
Larsen score at year 5, median (IQR) 6 (0-22) 6 (0-23) 6 (0-23) 
Patients with erosive disease at year 
5(%) 
46 46 45 
HAQ score at year 5, median (IQR) 0.8125 (0.125-1.625) 0.875 (0.125-1.625) 0.75 (0.125-1.625) 
DAS28 at year 5, median (IQR) 2.71 (2.02-3.75) 2.73 (2.02-3.79) 2.67 (2.02-3.64) 
CRP at year 5, median (IQR) 6.4 (0-14.2) 6.4 (0-14.1) 6.6 (0-14.7) 
  
 
 
 
 
 
 
Supplementary Table 2. Data availability for longitudinal modelling of different measures of disease outcome or activity 
Characteristics of NOAR patients are shown for the whole cohort (inflammatory polyarthritis - IP), irrespective of the availability of 
genotype information. The duration of follow-up and frequency of assessment, therefore the total number of time points, vary widely 
between different measures of disease outcome. For example, a max. of 4 time points per patients over 15 years is available to 
model DAS28, while some patients will have had their HAQ score measured 13 times over 20 years. The data presented in this 
table is used to model the effect of disease duration or age on different measures of disease outcome or activity (see 
Supplementary figure 1): radiographic outcome can be either the presence of erosive disease, the number of erosive joints or the 
Larsen score; SJC (swollen joint count); TJC (tender joint count). 
 
 
 
 
 
  Radiographic outcome HAQ score DAS28 SJC TJC CRP 
Total number of patients 1458 2347 2187 2350 2350 2200 
Total number of follow-ups (time points) 2402 14294 3781 10806 10806 3971 
Duration of follow-up in yrs, mean (max) 2.6 (10) 4.1 (20) 3.7 (15) 3.3 (20) 3.3 (20) 3.8 (15) 
Number of follow-ups per patient, mean (range) 1.5 (1-5) 4.4 (1-13) 1.6 (1-4) 3.1 (1-8) 3.1 (1-8) 1.6 (1-4) 
